Journal Article

DKFZ-2026-00814

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Excellent Response to Combined 223Ra-dichloride and Enzalutamide After Failure of 177Lu-PSMA Radioligand Therapy.

Calderón, E. ; Späth, M. S. ; Maas, M. ; la Fougère, C.DKFZ* ; Trautwein, N. F.

2026
Lippincott Williams & Wilkins Philadelphia, Pa.

Abstract: We report an 81-year-old man with metastatic castration-resistant prostate cancer (mCRPC) after multiple prior therapies, including androgen deprivation therapy (ADT), the androgen receptor pathway inhibitor (ARPI) abiraterone, taxane chemotherapy with docetaxel and cabazitaxel, radiopharmaceutical therapy (RPT) with 4 cycles of [177Lu]PSMA-I&T, and the PARP inhibitor olaparib in combination with abiraterone. Due to biochemical and clinical progression, [18F]PSMA-1007 PET/CT was performed for restaging, revealing diffuse skeletal metastases without significant extraosseous disease. Based on this imaging pattern, treatment with the ARPI enzalutamide combined with 223Ra-dichloride was initiated, resulting in an excellent response with a >90% PSA decline and a progression-free survival of 10 months.

Keyword(s): PSMA radioligand therapy ; androgen receptor pathway inhibitor ; prostate cancer ; targeted alpha therapy

Note: #DKTKZFB9# / epub

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Tübingen (TU01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2026

---

Database coverage:
; Allianz-Lizenz ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---